返回排名列表

The Cooper Companies, Inc. (COO)

NEUTRAL
HealthcareMedical Instruments & SuppliesUnited States

基本面

57

价格

$73.38

市值

-

第一部分 · 这家公司值多少

概览

Cooper Companies makes two very different kinds of medical products under one roof: contact lenses, sold through eye-care professionals to people who need vision correction, and instruments and devices used in women's health and fertility clinics — from surgical tools to the equipment IVF labs use to handle embryos. The two businesses share little beyond a corporate parent and a fiscal calendar.

盈利方式

The lens business is a recurring-purchase model: contact lenses wear out and are reordered regularly, so once a patient is fitted with a brand, replacement sales tend to continue for years. The surgical and fertility business instead sells instruments, disposable devices and lab equipment to clinics and hospitals — some of it capital equipment bought once, some of it consumables reordered with each procedure. Growth in each half of the company depends on different things: population trends in vision correction for one, and clinic capacity and IVF cycle volumes for the other.

分部营收

CooperVision67%

Soft contact lenses, including daily-disposable and specialty lenses that slow the progression of myopia in children.

CooperSurgical33%

Surgical instruments and devices for women's health, plus lab equipment and consumables used in fertility clinics for IVF.

护城河

转换成本 · 狭窄

A patient fitted and comfortable with a specific contact lens rarely switches brands on their own initiative, and an eye-care professional who has standardized on a fitting set has a mild reason to keep prescribing it. Neither habit is unbreakable: a competing lens of similar quality, or a clinic's own procurement decision, can still displace it.

需求驱动因素

防御型

Vision correction is an ongoing need regardless of the economy, which supports the lens business through downturns. The fertility side is more sensitive to discretionary spending and to clinics' own capital budgets: equipment purchases can be postponed when clinics turn cautious, even if underlying procedure demand holds up.

主要风险

  • Competition from larger diversified companies — In women's health and fertility, CooperSurgical competes against much larger medical-device companies with broader product lines and greater resources, which can give them an edge in marketing and bundled deals.
  • Reimbursement and pricing pressure — Changes in third-party coverage and reimbursement, and pricing pressure from competitors, can reduce demand or margins on both contact lenses and medical devices.
  • Clinic capital spending cycles — Fertility clinics have shown caution in equipment purchases in soft periods, which slows CooperSurgical's capital-equipment sales even when procedure volumes are stable.

看多理由

Buyers argue that steady population growth in myopia and an ageing population needing vision correction give CooperVision durable demand, that specialty myopia-control lenses carry better pricing than commodity lenses, and that CooperSurgical's fertility business benefits from a long-term rise in IVF procedure volumes.

看空理由

Sellers fear that contact lenses are a largely commoditized product exposed to pricing pressure from larger competitors, that combining two unrelated businesses under one roof makes capital allocation harder to judge from outside, and that fertility clinics' capital spending can stay soft for longer than expected.

Written by the editors, published on 2026年8月18日

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

资产负债表与流动性

营收

$4.23B

最近12个月(截至2026/4/30)

净利润

$236M

最近12个月(截至2026/4/30)

自由现金流

$434M

股东权益合计

$8.24B

负债合计

$4.16B

流动比率

1.27

利息覆盖率

5.35

债务/EBITDA

2.89

每股收益

营收与净利润

自由现金流

收入构成

历史财务表

利润率变化

债务变化

债务负担有多重

增长一览表

增长 — 营业收入

公允价值估算

被高估

公允价值

$51.44

当前价格

$73.38

安全边际

-42.6%

公允价值区间

$33.44 - $69.44

估算方法

Analyst Target:$81.50
DCF:$62.70
PE-based:$17.49
Graham Growth:$28.14
EPV:$22.56
分析师共识:买入 (13B / 10H / 0S)
最近财报超预期:+9.30%

估值指标

市盈率(P/E)

64.79

ROE

4.6%

市净率(P/B)

1.79

P/FCF

25.96

毛利率

65.5%

ROIC

3.7%

盈利能力雷达图

Value Creation (Economic Moat)

ROIC

3.7%

WACC

7.9%

ROIC − WACC

-4.2 pp

ROIC is below the cost of capital — the company is destroying value for every dollar invested.

基本面分析标准

通过(18)

  • EPS shows upward trend
  • Price CAGR 5.71%
  • Gross Margin 65.5%
  • P/FCF 25.96
  • P/B Ratio 1.79
  • Debt/Equity ratio
  • Operating Margin 11.8%
  • Positive Free Cash Flow
  • Current Ratio
  • Interest Coverage
  • Debt/EBITDA
  • Return on Tangible Assets
  • Revenue Growth 5Y 11.0%
  • Analyst Consensus 57% Buy
  • Earnings Surprise avg 4.8%
  • Earnings Quality (OCF/NI) 4.04
  • Share Dilution 0.2%
  • Piotroski F-Score 6/9

未通过(9)

  • EPS CAGR 1.63%
  • ROIC 3.7%
  • CapEx intensity
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • ROE 2.8%
  • PEG Ratio 6.85
  • Net Margin Trend 5.6% vs 10.4%

不可用(1)

  • Dividend Payout NaN%

Piotroski F-评分

6/9

信号混杂:部分领域需关注

score
criteria

盈利质量

4.04

高质量:盈利有现金流支撑

股权稀释

0.2%

股份数量稳定

公司治理

管理团队

姓名职位年龄
Mr. Albert G. White IIIPresident, CEO & Non-Independent Director55
Mr. Daniel G. McBride Esq.Executive VP, COO General Counsel & Secretary61
Ms. Holly R. SheffieldPresident of CooperSurgical, Inc.54
Mr. Gerard H. Warner IIIPresident of CooperVision, Inc.60
Mr. Kim DuncanVice President of Investor Relations & Risk Management-

审计风险

10

董事会风险

3

薪酬风险

9

股东权利风险

3

第二部分 · 价格与买入时机

这一部分不判断公司是否值得拥有:它帮助你在基本面说服你之后,选择何时买入。包含:技术分析、潜力、历史回撤、Gamma 敞口。

Latest News

Recent headlines for COO, sourced from Markets Gazette.

  • 6/4/2026NEUTRAL
    Full Transcript: Cooper Companies Q2 2026 Earnings Call

    The Cooper Companies (COO) released its Q2 2026 earnings call transcript. While the transcript itself is a factual record of the discussion, it does not contain immediate financial results or forward-looking guidance that would directly impact the stock price. Investors will need to analyze the content of the call, including management's commentary on performance, market conditions, and future outlook, to derive actionable insights. The transcript serves as a source document for deeper fundamental analysis rather than an immediate trading signal.

  • 3/5/2026NEUTRAL
    Cooper (COO) Q1 2026 Earnings Call Transcript

    The Q1 2026 earnings call transcript for Cooper Industries plc (COO) has been released. This document provides details on financial performance, business strategies, and future outlook. While specific figures are not available in this summary, earnings call transcripts are crucial for investors to assess a company's financial health, understand challenges and opportunities, and gain insights into future guidance. A thorough analysis of this transcript could reveal signals of growth or slowdown.

  • 3/5/2026NEUTRAL
    Cooper Companies Earnings Review: Q1 Summary

    Cooper Companies Inc. released its first-quarter results, showing performance in line with analyst expectations. Revenue stood at $920 million, up 6% year-over-year, while adjusted earnings per share came in at $3.80, matching the consensus. The Vision Care division led growth with a 7% increase, while the Women's Health division saw a 5% rise. Guidance for the second quarter was reaffirmed, indicating a stable outlook. For investors, the news confirms the resilience of Cooper Companies' business model, but without any surprises to trigger significant stock movement.

via Markets Gazette